Compare Inovio Pharmaceuticals Inc (INO) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Lululemon Athletica Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Lululemon Athletica Inc trades at $115.01 (market cap $13.25B). The key difference: Lululemon Athletica Inc is far larger — about 148.4× Inovio Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| INO | LULU | |
|---|---|---|
Market Cap | $89.27M | $13.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $224.03 |
52-Week Low | $1.05 | $105.43 |
Enterprise Value | $60.28M | $13.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Lululemon trades at $116.79, up 0.4% on the day, with a bearish technical signal but strong fundamentals including a 13.03% net margin and 32.03% ROE. Recent earnings beats and a $30M investment in nylon recycling startup Syntetica highlight growth initiatives, though the stock faces headwinds from North American weakness and a class-action lawsuit over tariff costs. The current price sits near pivot point resistance at $117.
The outlook is mixed: valuation metrics like a 9.42 P/E suggest potential upside to the $129.29 consensus target, but bearish technicals and competitive pressures pose risks. Investment opportunity lies in robust cash flow and buyback potential, while key risks include brand controversies and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
